ASH 2022 | Outcomes of patients with myeloma receiving fixed-duration cevostamab
Joshua Richter, MD, Mount Sinai Medical Center, New York, NY, discusses a Phase I trial (NCT03275103) investigating fixed-duration cevostamab therapy for patients with relapsed multiple myeloma. The study found that responses were maintained for up to six to 12 months after end of treatment in some patients, giving the patients the benefit of a break from treatment without compromising outcomes. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Secura Bio: Consultancy, Honoraria; Takeda: Consultancy; Oncopeptides: Consultancy, Honoraria; BMS/Celgene: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau.
